Viridian Therapeutics Statistics
Share Statistics
Viridian Therapeutics has 79.21M shares outstanding. The number of shares has increased by 45.2% in one year.
| Shares Outstanding | 79.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 19.64% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 70.47M |
| Failed to Deliver (FTD) Shares | 51 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 10.02M, so 12.65% of the outstanding shares have been sold short.
| Short Interest | 10.02M |
| Short % of Shares Out | 12.65% |
| Short % of Float | 14.29% |
| Short Ratio (days to cover) | 12.51 |
Valuation Ratios
The PE ratio is -4.1 and the forward PE ratio is -5.6.
| PE Ratio | -4.1 |
| Forward PE | -5.6 |
| PS Ratio | 3104.38 |
| Forward PS | 6082.9 |
| PB Ratio | 2.21 |
| P/FCF Ratio | -5.27 |
| PEG Ratio | n/a |
Enterprise Valuation
Viridian Therapeutics Inc. has an Enterprise Value (EV) of 893.00M.
| EV / Earnings | -3.76 |
| EV / Sales | 2843.93 |
| EV / EBITDA | -3.81 |
| EV / EBIT | -3.51 |
| EV / FCF | -4.83 |
Financial Position
The company has a current ratio of 18.26, with a Debt / Equity ratio of 0.05.
| Current Ratio | 18.26 |
| Quick Ratio | 18.26 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.37 |
| Cash Flow / Debt | -9.12 |
| Interest Coverage | -137.76 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on capital (ROIC) is -54.95%.
| Return on Equity (ROE) | -0.54% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -54.95% |
| Revenue Per Employee | 3.34K |
| Profits Per Employee | -2.53M |
| Employee Count | 94 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -14.14% in the last 52 weeks. The beta is 1.11, so Viridian Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | -14.14% |
| 50-Day Moving Average | 21.59 |
| 200-Day Moving Average | 17.31 |
| Relative Strength Index (RSI) | 45.36 |
| Average Volume (20 Days) | 1.27M |
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 314.00K and earned -237.73M in profits. Earnings per share was -5.31.
| Revenue | 314.00K |
| Gross Profit | -1.01M |
| Operating Income | -254.45M |
| Net Income | -237.73M |
| EBITDA | -234.56M |
| EBIT | -254.45M |
| Earnings Per Share (EPS) | -5.31 |
Balance Sheet
The company has 102.83M in cash and 21.05M in debt, giving a net cash position of 81.78M.
| Cash & Cash Equivalents | 102.83M |
| Total Debt | 21.05M |
| Net Cash | 81.78M |
| Retained Earnings | -725.91M |
| Total Assets | 771.90M |
| Working Capital | 725.99M |
Cash Flow
In the last 12 months, operating cash flow was -184.17M and capital expenditures -898.00K, giving a free cash flow of -185.07M.
| Operating Cash Flow | -184.17M |
| Capital Expenditures | -898.00K |
| Free Cash Flow | -185.07M |
| FCF Per Share | -4.14 |
Margins
Gross margin is -321.02%, with operating and profit margins of -81.04K% and -75.71K%.
| Gross Margin | -321.02% |
| Operating Margin | -81.04K% |
| Pretax Margin | -75.71K% |
| Profit Margin | -75.71K% |
| EBITDA Margin | -74.70K% |
| EBIT Margin | -81.04K% |
| FCF Margin | -58.94K% |
Dividends & Yields
VRDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -27.5% |
| FCF Yield | -12.1% |
Analyst Forecast
The average price target for VRDN is $34, which is 76.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $34 |
| Price Target Difference | 76.1% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Stock Splits
The last stock split was on Nov 13, 2020. It was a backward split with a ratio of 1:15.
| Last Split Date | Nov 13, 2020 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 12.91 |
| Piotroski F-Score | 3 |